145 related articles for article (PubMed ID: 37686472)
1. Specific Targeting of STAT3 in B Cells Suppresses Progression of B Cell Lymphoma.
Wang L; Zhou M; Kong X; Wu S; Ding C; Hu X; Guo H; Yan J
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686472
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
[TBL] [Abstract][Full Text] [Related]
3. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
4. [Growth inhibition of breast cancer cells in vitro and in vivo by siRNA targeting signal transducers and activators of transcription 3].
Yang Z; Yan L; Zhang F; Yan QH; Song WQ; Wang FA; Cai JH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):819-24. PubMed ID: 21223686
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription 3 downregulation in J774A.1 cell line as a model of M2 macrophages in tumor microenvironment.
Seyedi Z; Hashemzadeh MR; Colagar AH; Jaafari MR
J Cancer Res Ther; 2018; 14(5):1121-1125. PubMed ID: 30197360
[TBL] [Abstract][Full Text] [Related]
8. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
[TBL] [Abstract][Full Text] [Related]
9. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
10. Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
Zhang Z; Zhao X; Wang D; Moreira D; Su YL; Alcantara M; Swiderski P; Wong J; Hui S; Forman S; Kwak L; Kortylewski M
Mol Ther; 2021 Mar; 29(3):1214-1225. PubMed ID: 33248246
[TBL] [Abstract][Full Text] [Related]
11. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.
Liu Y; Deng J; Wang L; Lee H; Armstrong B; Scuto A; Kowolik C; Weiss LM; Forman S; Yu H
Blood; 2012 Aug; 120(7):1458-65. PubMed ID: 22745305
[TBL] [Abstract][Full Text] [Related]
12. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.
Wang GM; Ren ZX; Wang PS; Su C; Zhang WX; Liu ZG; Zhang L; Zhao XJ; Chen G
Oncol Rep; 2014 Aug; 32(2):573-80. PubMed ID: 24899100
[TBL] [Abstract][Full Text] [Related]
13. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
14. [Small interfering RNA suppression of transducer and activator of transcription 3 (STAT3) signaling pathway: inhibitory effect on proliferation of human esophageal squamous carcinoma cells].
Wang XH; Li SS; Yan AH; Sun Y; Lu CX; Guo YP
Zhonghua Bing Li Xue Za Zhi; 2007 Jun; 36(6):379-83. PubMed ID: 17822622
[TBL] [Abstract][Full Text] [Related]
15. SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells.
Huang LL; Rao W
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4098-4106. PubMed ID: 30024597
[TBL] [Abstract][Full Text] [Related]
16. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
17. Effect of STAT3 inhibition on the metabolic switch in a highly STAT3-activated lymphoma cell line.
Akiyama Y; Iizuka A; Kume A; Komiyama M; Urakami K; Ashizawa T; Miyata H; Omiya M; Kusuhara M; Yamaguchi K
Cancer Genomics Proteomics; 2015; 12(3):133-42. PubMed ID: 25977172
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
19. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer.
Kunigal S; Lakka SS; Sodadasu PK; Estes N; Rao JS
Int J Oncol; 2009 May; 34(5):1209-20. PubMed ID: 19360334
[TBL] [Abstract][Full Text] [Related]
20. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
